Synthetic lethal targeting of TET2 ‐mutant haematopoietic stem and progenitor cells by XPO1 inhibitors
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18667 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Chang-Bin Jing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Dioxygenases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Edward P. Evans Foundation, Lady Tata Memorial Trust.
Abstract (Originalsprache)
TET2 inactivating mutations serve as initiating genetic lesions in the transformation of haematopoietic stem and progenitor cells (HSPCs). In this study, we analysed known drugs in zebrafish embryos for their ability to selectively kill tet2 ‐mutant HSPCs in vivo. We found that the exportin 1 (XPO1) inhibitors, selinexor and eltanexor, selectively kill tet2 ‐mutant HSPCs. In serial replating colony assays, these small molecules were selectively active in killing murine Tet2 ‐deficient Lineage‐, Sca1+, Kit+ (LSK) cells, and also TET2 ‐inactivated human acute myeloid leukaemia (AML) cells. Selective killing of TET2 ‐mutant HSPCs and human AML cells by these inhibitors was due to increased levels of apoptosis, without evidence of DNA damage based on increased γH2AX expression. The finding that TET2 loss renders HSPCs and AML cells selectively susceptible to cell death induced by XPO1 inhibitors provides preclinical evidence of the selective activity of these drugs, justifying further clinical studies of these small molecules for the treatment of TET2 ‐mutant haematopoietic malignancies, and to suppress clonal expansion in age‐related TET2 ‐mutant clonal haematopoiesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
- Karyopharm Therapeutics, Newton, Massachusetts, USA.
- Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: A Thomas Look
Förderung
- NCI NIH HHS
- Edward P. Evans Foundation
- Lady Tata Memorial Trust
- Lymphoma Research Foundation
- National Institutes of Health
Zitieren
APA
Jing, C. B., Prutsch, N., He, S., Zimmerman, M. W., Landesman, Y., & Look, A. T. (2023). Synthetic lethal targeting of TET2 ‐mutant haematopoietic stem and progenitor cells by XPO1 inhibitors. British Journal of Haematology. https://doi.org/10.1111/bjh.18667
Vancouver
Jing CB, Prutsch N, He S, Zimmerman MW, Landesman Y, Look AT. Synthetic lethal targeting of TET2 ‐mutant haematopoietic stem and progenitor cells by XPO1 inhibitors. British Journal of Haematology. 2023. doi:10.1111/bjh.18667
BibTeX
@article{Jing2023,
author = {Jing, Chang-Bin and Prutsch, Nicole and He, Shuning and Zimmerman, Mark W and Landesman, Yosef and Look, A Thomas},
title = {Synthetic lethal targeting of TET2 ‐mutant haematopoietic stem and progenitor cells by XPO1 inhibitors},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18667}
}
EUVIMED